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Abstract
Purpose: New treatments are introduced into standard care based on clinical trial
results. However, it is not clear if these benefits are reflected in the broader popula-
tion. This study analysed the clinical outcomes of patients with metastatic castration-
resistant prostate cancer, treated with abiraterone and enzalutamide, within the
Scottish National Health Service.
Methods: Retrospective cohort study using record linkage of routinely collected
healthcare data (study period: February 2012 to February 2017). Overall survival
(OS) was analysed using Kaplan-Meier methods and Cox Proportional Hazard models;
a subgroup analysis comprised potentially trial-eligible patients.
Results: Overall, 271 patients were included and 73.8% died during the study period.
Median OS was poorer than in the pivotal trials, regardless of medication and indica-
tion: 10.8 months (95% confidence interval [CI] 8.6-15.1) and 20.9 months (95% CI
14.9-29.0) for abiraterone, and 12.6 months (95% CI 10.5-18.2) and 16.0 months
(95% CI 9.8—not reached) for enzalutamide, post and pre chemotherapy, respec-
tively. Only 46% of patients were potentially “trial eligible” and in this subgroup OS
improved. Factors influencing survival included baseline performance status, and
baseline prostate-specific antigen, alkaline phosphatase, and albumin levels.
Conclusions: Poorer prognostic features of non-trial eligible patients impact real-
world outcomes of cancer medicines. Electronic record linkage of routinely collected
healthcare data offers an opportunity to report outcomes on cancer medicines at
scale and describe population demographics. The availability of such observational
data to supplement clinical trial results enables patients and clinicians to make more
informed treatment decisions, and policymakers to contextualise trial findings.
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1 | INTRODUCTION
Cancer medicines account for a high proportion of all newly licensed
medicines globally. In 2017, for example, a quarter of all medicines
approved by the European Medicines Agency (EMA) and 26% of novel
substances approved by the United States Food and Drug Administra-
tion (FDA) were for cancer indications.1,2
A recent review of cancer medicines approved in Europe and the
USA over the last decade found an average overall survival
(OS) benefit as demonstrated in randomised clinical trials (RCTs) of
3.4 months; there were, nevertheless, wide variations across trials.3
Abiraterone and enzalutamide, for instance, indicated in patients with
metastatic castration-resistant prostate cancer (mCRPC) in addition to
standard androgen deprivation therapy, have shown significant
benefits in the pivotal trials initially when given after docetaxel-based
chemotherapy (post chemotherapy) and subsequently also in
chemotherapy-naïve patients (pre chemotherapy), with median OS
ranging from 15.8 months (95% confidence interval [CI] 14.8-17.0) in
patients treated with abiraterone post chemotherapy to 35.3 months
(95% CI 32.2-not reached) in pre-chemotherapy patients treated with
enzalutamide.4-10
However, patient characteristics and treatment outcomes
reported in a clinical trial population may not be representative of
those seen in clinical practice as, by design, trial cohorts are restrictive,
and participants often have fewer significant comorbidities than might
be found in a broader real-world population.11,12 As a result, real-world
studies frequently describe considerably shorter OS than that reported
from clinical trials, including studies analysing the use of abiraterone
and enzalutamide,13-16 although some studies have found OS rates
similar to the pivotal trials.13,17,18 Consequently, a recent study per-
spective proposed that OS obtained from clinical trials should only be
considered a surrogate endpoint for OS in the real world.19
As access to cancer medicines is a prominent matter of public
interest and healthcare policy, policymakers—particularly in publicly
funded healthcare systems such as the National Health Service (NHS)
in the UK—would benefit from an improved understanding of whether
these treatments deliver the same outcomes in clinical practice as
demonstrated in Health Technology Assessments (HTAs), which are
almost exclusively based on clinical trials data. There is a growing
demand to develop more efficient methods to better identify the ben-
efits and risks of new treatments, and thus to assure the most effec-
tive use of available resources, particularly with the increasing
pressures of early licensing. Observational data have the potential to
supplement the existing appraisal processes with medicines effective-
ness data obtained from real-world populations.
In 2016, funding was made available in Scotland as part of the
“Beating Cancer: Ambition and Action” Cancer Plan,20 to deliver the
Cancer Medicines Outcomes Programme (CMOP). The CMOP vision
is to maximise the use of the existing and evolving local and national
electronic datasets to better understand treatment outcomes of can-
cer medicines in the Scottish population. The methodology is
designed to grow scalable and sustainable expertise in cancer medi-
cines intelligence to drive continuous improvement in the safe and
effective use of these medicines, and thereby to contribute to the
international evidence base. During its initial funding phase, CMOP
has sought to deliver an incremental programme of studies to test the
availability and record linkage capacity of routinely collected clinical
datasets within a region of Scotland.
Prostate cancer was chosen as an initial CMOP case study, as it is
the most common male cancer and was the second most common cause
of death in men in the United Kingdom in 2017.21 TheWest of Scotland
Clinical Management Guidelines for mCRPC patients include both
abiraterone and enzalutamide, and selection of treatment is made jointly
by clinicians and patients taking into consideration individual patient fac-
tors and expected side effect profile.22 Prostate-specific antigen (PSA) is
an important molecular marker in the diagnosis and management of
prostate cancer and is used alongside the Gleason score and clinical
staging to evaluate the prognosis of newly diagnosed patients.23
Key points
• Median overall survival in patients with metastatic castra-
tion-resistant prostate cancer treated with abiraterone
and enzalutamide in clinical practice is less than was
observed in the pivotal trials.
• Treatment outcomes were impacted by poorer prognos-
tic factors exhibited by non-trial eligible patients.
• The majority of patients being treated with abiraterone
and enzalutamide in clinical practice would not have been
eligible for inclusion in the pivotal trials that led to the
approval of these medicines.
• Linked, electronic data sources can be used at a popula-
tion level to describe patient demographics, estimate trial
eligibility, and analyse outcomes of cancer medicines in
clinical practice.
• This information, alongside clinical trial findings, may
enable a more informed discussion of the likely outcomes
of treatment, particularly with patients who do not fit
clinical trial eligibility criteria; and facilitates a better
understanding of the outcomes associated with these
medicines in the “real world.”
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The purpose of this study was to demonstrate the feasibility of
using electronic record linkage (ERL) to measure real-world outcomes
of cancer medicines by determining treatment outcomes of
abiraterone and enzalutamide in clinical practice in Scotland. Specific
objectives were to:
• Calculate OS in patients with mCRPC treated with abiraterone and
enzalutamide, and descriptively compare findings to results
obtained in the respective clinical trials;
• Identify potentially trial-eligible patients, and explore outcomes in
this subgroup; and
• Analyse factors influencing survival.
2 | METHODS
2.1 | Study design and participants
The study was designed as a retrospective cohort study, applying
ERL of routinely collected healthcare data in Scotland. The study
population included all patients treated with either abiraterone or
enzalutamide within NHS Greater Glasgow & Clyde (GGC). Patients
were stratified as to whether or not they had previously received
chemotherapy for their mCRPC in accordance with the pivotal clini-
cal trials. NHS GGC is the largest Health Board in Scotland and pro-
vides universal access to healthcare for a population of
approximately 1.2 million.
All patients who commenced treatment between February 2012
and December 2015 were identified via the Chemotherapy Electronic
Prescribing and Administration System (CEPAS). CEPAS was
implemented into NHS GGC systems in December 2010 and is now
used for all Systemic Anti-Cancer Therapy (SACT) prescribing within
the region.24 Dates for cohort inclusion were chosen based on the
timing of medicine approval in Scotland and data availability, allowing
for sufficient follow-up time. Patients were excluded if they participated
in a clinical trial (except where the medicine was used within its product
label), or if they received both abiraterone and enzalutamide during the
recruitment period. Patients were followed up until death or the end of
the study period (February 28, 2017), whichever occurred first.
2.2 | Data sources
A range of data, comprising patient demographics, diagnostic details,
and information regarding previous, current, and subsequent treat-
ments, were gathered from a number of separate databases used in
routine care (Table 1). Records were linked via Community Health
Index (CHI) numbers, a unique patient identifier used throughout the
NHS to identify individual patients.25
Trial eligibility criteria were identified through published proto-
cols4-7 and, where possible, mapped onto appropriate criteria identi-
fied in the datasets. This allowed the selection of a subset of patients
likely to have fulfilled the trial selection criteria; and to subsequently
compare results with those from published pivotal studies.
TABLE 1 Data sources for exposure and outcome variables used in the record linkage
Data source Content Purpose Example variables
Chemotherapy Electronic Prescribing
System (CEPAS)26
Systemic anti-cancer therapy
(SACT) prescribing for all
NHS patientsa
Identification of study
population; medicine
exposure
SACT medicine, dose, indication,
treatment dates
Scottish Cancer Registry (SMR06)27 New cancer diagnosesb Disease-related details Diagnosis (ICD-10), date of diagnosis,
Gleason score
ARIA26 Radiotherapy records Previous/subsequent
treatment
Dose/fraction, indication, appointment
date
Scottish Care Information (SCI store)27 Laboratory test results Baseline bloods; PSA levels Type of test, test date, value
Scottish Morbidity Records, Inpatient and
Day Case dataset (SMR01)27
Episode level data on acute
hospital admissions
Comorbidities; previous/
subsequent treatment
Diagnosis (ICD-10), admission date,
length of stay, procedures undertaken
Scottish Morbidity Records, Outpatient
Attendance dataset (SMR00)27
Episode level data on
outpatient clinic attendances
Comorbidities; previous/
subsequent treatment
Diagnosis (ICD-10), appointment date,
procedures undertaken
Prescribing Information System (PIS)28 Primary care prescribing for all
NHS patientsc
Comorbidities; previous/
subsequent treatment
Medicine, dose, quantity, prescription
dates
National Records of Scotland (NRS)27 Registration of life events Determine outcome (death) Date and cause of death
Abbreviations: ICD-10, International Classification of Disease, 10th edition; NHS, National Health Service; PSA, prostate-specific antigen; SACT, systemic
anti-cancer therapy.
aCEPAS is a comprehensive source of data of all SACT prescriptions within the NHS in the West of Scotland (WoS). The numbers of patients receiving
SACT within private healthcare are not known but are presumed to be very small due to the nature of the NHS (universal access, with services free at the
point of delivery).
bSMR06 captures information such as TNM staging at initial diagnosis only.
cPIS does not contain information about medicines dispensed/administered in secondary care.
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2.3 | Treatment outcome measures
The primary outcome measure was OS. The duration of treatment
was a key secondary endpoint. February 28, 2017, served as the cen-
sor date for those patients event free at study end.
2.4 | Statistical analysis
Total median follow-up was calculated in two ways. First, for descrip-
tive purposes, using median total observation time (time from treat-
ment initiation until death or censoring), and second, using median
Kaplan-Meier estimate of potential follow-up to allow comparability
between groups or studies with differing death rates.29 Median time to
event, along with 95% CIs, were estimated using the Kaplan-Meier
method. Cox Proportional Hazard models were used to estimate
unadjusted hazard ratios for survival, stratified by pre- and post-
chemotherapy medication use. To estimate the impact of prognostic vari-
ables on OS, multivariable Cox Proportional Hazard models—adjusted for
Charlson comorbidity index (CCI) score and/or number of different medi-
cines used concomitantly at baseline—were created using variables with
P < 0.2 from the univariable analyses; the proportionality assumptions
were tested using Schoenfeld residuals. In addition to the main analysis,
subgroup analyses were undertaken for patients who would potentially
have been eligible/non-eligible for inclusion in the respective trials.
All analyses were performed using the R software, version 3.3.3.
3 | RESULTS
3.1 | Patient baseline characteristics
A total of 288 patients initiated treatment with abiraterone or
enzalutamide between February 2012 and December 2015. Seventeen
patients were subsequently excluded due to having received both medi-
cines during this period; hence, 271 patients were included in the analy-
sis (Figure 1).
Baseline characteristics at treatment initiation for all patients,
stratified by medicine and indication and also including those from the
respective clinical trials, are summarised in Table 2.
3.2 | Duration of treatment
The median duration of treatment was 9.8 months (95% CI 7.4-11.7)
for abiraterone and 7.6 months (95% CI 6.2-10.8) for enzalutamide.
Treatment duration was shorter in patients post chemotherapy, with
7.7 months (95% CI 5.7-11.1) in the abiraterone and 7.0 months (95%
CI 4.1-10.5) in the enzalutamide group. Amongst patients treated prior
to chemotherapy, the median duration of treatment was 11.1 months
for both drugs (95% CI abiraterone 9.2-14.9; 95% CI enzalutamide
6.5-15.7). At study end, a total of 36 of the 71 patients alive (51%)
remained on treatment: 20/34 (59%) on abiraterone and 16/37 (43%)
on enzalutamide—however, for both medications, proportions were
considerably higher in the pre-chemotherapy groups (59% for both
abiraterone and enzalutamide patients; and 50% and 29% for post-
chemotherapy abiraterone and enzalutamide, respectively).
3.3 | Trial eligibility
A total of 70 different eligibility criteria were identified across the
four trials4-7:19 inclusion criteria and 51 exclusion criteria. On average,
64% of inclusion criteria (range 44%-82% between trials) and 55% of
exclusion criteria (range 33%-74%) could be determined (Table S1).
Amongst the 261 patients being treated with abiraterone or
enzalutamide either pre or post chemotherapy, an estimated 121 (46%)
would have met the clinical trial eligibility criteria. Patients in the
F IGURE 1 Flow chart
identification of cohort population
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pre-chemotherapy group were less likely to have matched the trial-
eligibility criteria (33% abiraterone, 38% enzalutamide) than in the post-
chemotherapy group (52% abiraterone, 55% enzalutamide); key ineligi-
bilities were laboratory test results outside the required parameters at
the time of screening; prior chemotherapy within a specified time frame
prior to starting treatment (amongst post-chemotherapy patients); and
concomitant medication at baseline in the enzalutamide groups.
There were differences in baseline characteristics between trial
eligible and ineligible patient populations, including higher baseline
PSA and alkaline phosphatase levels amongst the non-trial eligible
patients; further details can be found in Tables S2 and S3.
3.4 | Treatment outcomes
At the end of the study period, 71 patients (26%) were still alive:
34 abiraterone patients (23%) and 37 enzalutamide patients (30%);
overall median OS were 14.6 months (95% CI 12.3-17.0) and
TABLE 2 Study and trial patient baseline characteristics, by drug and indication
Abiraterone Enzalutamide
Post chemo
Post
chemo—
trial5 Pre chemo
Pre
chemo—
trial4 Post chemo
Post
chemo—
trial6 Pre chemo
Pre
chemo—
trial7
Number patients 82 797 63 546 74 800 42 872
Age (years)
Median (IQR) 73 (67.3-76.8) 69 75 (70.5-81) 71 72 (68-79) 69 77.5 (73-81) 72
Range 52-85 42-95 58-93 44-95 49-88 41-92 63-92 43-93
Number patients ≥ 75 years
N (%) 28 (34%) 220 (28%) 32 (51%) 185 (34%) 26 (35%) 199 (25%) 27 (64%) 317 (36%)
Baseline ECOG performance status
0-1 40 (49%) 715 (90%) 36 (57%) 546 (100%) 42 (57%) 730 (91%) 20 (48%) 872 (100%)
2-3 6 (7%) 82 (10%) 10 (16%) 0 6 (8%) 70 (9%) 7 (17%) 0
Unavailable 36 (44%) 0 17 (27%) 0 26 (35%) 0 15 (36%) 0
Gleason score at diagnosis
≤7 21 (26%) 341 (43%) 16 (25%) 225 (41%) 6 (8%) 360 (45%) 7 (17%) 414 (47%)
≥8 40 (49%) 356 (45%) 29 (46%) 263 (48%) 53 (72%) 366 (46%) 17 (41%) 424 (49%)
Unavailable 21 (26%) 100 (12%) 18 (29%) 58 (11%) 15 (20%) 74 (9%) 18 (43%) 34 (4%)
Only one prior chemotherapy regimen
N (%) 79 (96%) 558 (70%) 0 0 72 (97%) 579 (72%) 0 0
Number prior docetaxel cycles
Median (IQR) 7 (4-10) 8 0 0 8 (4-10) 8.5 0 0
Range 1-13 n/a 0 0 1-10 n/a 0 0
Baseline PSA (μg/L)
Median (IQR) 147.9 (27.4-430.8) 128.8 43.5 (13.8-93.4) 42 95.9 (39-260.6) 107.7 56.2 (15.2-167.9) 54.1
Range 0.1-7571 0.4-9253 0.1-6568 0-3927.4 5.1-6308 0.2-11794 2.1-3689 0.1-3182
Unavailable 8 (9.8%) 9 (1%) 9 (14.3%) 0 5 (6.8%) 0 11 (26.2%) 0
Baseline haemoglobin (g/L)a
Median (IQR) 116 (99-129) 118 125 (112-136.5) n/a 119.5 (105-127.8) 120 125.5 (113-132) 130
Range 77-164 73-161 74-151 n/a 67-149 63-156 85-164 82-168
Baseline alkaline phosphatase (IU/L)a
Median (IQR) 171.5 (109.5-333.8) n/a 121 (83-182) 93 165 (106.8-289) n/a 129 (93.5-301.5) 94
Range 53-1126 n/a 49-2172 32-1972 32-3140 n/a 57-1903 34-4485
Baseline albumin (g/L)a
Median (IQR) 33 (27-37) n/a 36 (32-48) n/a 33 (30-36) 38 35 (32-37.5) 38
Range 16-42 n/a 22-45 n/a 20-43 26-50 25-41 25-48
Abbreviations: Chemo, Chemotherapy; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; N, number; n/a, not available; PSA, prostate
specific antigen.
aNumber of patients with missing data not reported due to some cells containing values <5.
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14.0 months (95% CI 11.5-18.2) amongst abiraterone and
enzalutamide patients, respectively. Observed median OS were less
than those reported from the pivotal clinical trials across all patient
groups, as detailed in Tables 3 and 4.
Results from univariable survival analyses indicated that trial eligi-
bility significantly affected survival in both the post- and pre-
chemotherapy groups, with Hazard Ratios of 1.69 (95% CI 1.2-2.37)
and 2.88 (95% CI 1.55-5.35) for potentially trial-eligible patients vs
non-eligible patients in the post-and pre-chemotherapy groups,
respectively. The subsequent subgroup analysis of those 121 patients
who would potentially have been trial eligible found improved OS
across all groups, and higher proportions of patients remained alive;
at the censor date, 16 (25%) of the abiraterone and 24 (42%) of the
enzalutamide patients were still alive. In particular, the OS amongst
post-chemotherapy patients was closer to the pivotal study results,
with the median OS estimated at 13.9 months (95% CI 9.8-18.3) and
18.2 months (95% CI 12.1-30.0) for abiraterone and enzalutamide,
respectively. Median OS for all patients, the potentially trial-eligible
and ineligible subgroups, and the pivotal trials are presented
in Tables 3 and 4, with Kaplan-Meier survival curves shown in
Figure 2.
3.5 | Factors influencing overall survival
Exploring the underlying prognostic characteristics which might
explain differences in OS between the real-world patients and those
included in the pivotal trials showed that a variety of individual factors
had an impact on survival in univariable analyses in the post- and/or
pre-chemotherapy group, including baseline performance status;
Gleason score; and baseline PSA, alkaline phosphatase, albumin, and
haemoglobin levels (see Table 5 for details).
In the fully adjusted multivariable analyses, factors that remained
independently associated with survival were baseline performance
status, and baseline PSA and alkaline phosphatase levels in the post-
chemotherapy group; and baseline performance status and baseline
PSA and albumin levels in the pre-chemotherapy group. For details,
see Table 5.
In addition, a complete case analysis has been conducted to
assess how sensitive the study results were to the missing data on
performance status. Briefly, findings were generally in line with those
obtained through the adjusted multivariable models containing miss-
ing data within the categorical variables; although some effect sizes
differed slightly, the direction of effects was the same. Details are
presented in Table S4.
4 | DISCUSSION
To our knowledge, this is the first study to demonstrate the use of
ERL of routinely collected data to obtain a comprehensive,
population-level assessment of treatment outcomes of cancer medi-
cines. Furthermore, by providing results based on a subgroup analysis
of potentially trial eligible patients, this study offers vital information
that helps contextualise real-world results in comparison to clinical
trials.
In line with other real-world studies, median OS in patients
treated with either abiraterone or enzalutamide in both the pre and
post-chemotherapy settings were less than in the respective pivotal
trials.13-16 However, there were important differences between
patients observed in clinical practice and the trial populations. In par-
ticular, the patients included in this study were older, and had poorer
performance status; patients with performance status >2 were
included within our study, but were excluded from all pivotal trials.4-7
TABLE 3 Outcomes in the post- and pre-chemotherapy abiraterone populations
Post chemotherapy abiraterone Pre chemotherapy abiraterone
Outcome
Patient group All patients
Trial eligible
patients
Trial ineligible
patients Pivotal study8 All patients
Trial eligible
patients
Trial ineligible
patients
Pivotal
study9
Number of
patients
82 43 39 797 63 21 42 546
Potential follow-up, KM estimate (months)
Median (95% CI) 39.4 (38.9 - NR) 38.9 (38.9 - NR) 39.4 (NR-NR) 16.3 (15.9-27.1) 16.6 (15.8 - NR) 16 (15.7- NR)
Observed follow-up (months)
Median (IQR) 10.7 (4.5-18.3) 13.9 (7.7-22.5) 7.3 (2.6-16.5) 20.2 (18.4-22.1) 15.0 (11.3-16.4) 15.9 (14.9-20.4) 14.3 (9.4-16.0) 49.2 (47.0-51.8)
Mean (SD) 13.0 (10.5) 14.8 (7.6)
Range 0.1-45.0 0.7-31.9
Total 1066.8 931.2
Patients alive at
censor datea
(5%) (<10%) (<5%) 296/797 (37%) 29/63 (46%) 13/21 (62%) 16/42 (38%) 192/546 (35%)
Overall survival
(95% CI) (months)
10.8 (8.6-15.1) 13.9 (9.8-18.3) 7.4 (4.6-15.1) 15.8 (14.8-17.0) 20.9 (14.9-29) 26.7 (20.4-NR) 14.9 (12.5-NR) 34.7 (32.7-36.8)
Abbreviations: CI, Confidence Interval; IQR, Inter Quartile Range; KM, Kaplan–Meier; NR, Not reached.
aNumbers of patients not reported if <5.
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In addition, patients had higher alkaline phosphatase levels at baseline,
and fewer patients had a Gleason score ≤7. Age and alkaline phospha-
tase were found to be significant prognostic factors in the abiraterone
pre chemotherapy RCT,9 whilst performance status was significant in
the enzalutamide post-chemotherapy trial6; conversely, the post-
chemotherapy trials did not include baseline albumin,5,6 and only the
pre-chemotherapy trials reported on baseline alkaline phosphatase
values.4,7 Comparing real-world findings to clinical trials data is always
a challenge, not least because settings, analytical methods and/or
study objectives may differ considerably; hence, in order to allow
truer comparisons with results based on observational studies, we
would advocate for individual-level data from trials to be made avail-
able. This would enable better replication of methods and offer
deeper, more meaningful insights. Nevertheless, the prognostic signifi-
cance of the patient characteristics as identified in this study also cor-
responds with previously published results based on observational
data11-13,30,31
The underlying impact of differences in patient characteristics as
an explanation for the differences observed between RCTs and clini-
cal practice has been confirmed by conducting a subgroup analysis of
those patients who would potentially have been trial eligible. In this
subgroup, median OS was higher than in the overall study population,
TABLE 4 Outcomes in the post- and pre-chemotherapy enzalutamide populations
Post chemotherapy enzalutamide Pre chemotherapy enzalutamide
Outcome
Patient group All patients
Trial eligible
patients
Trial ineligible
patients Pivotal study6 All patients
Trial eligible
patients
Trial ineligible
patients Pivotal study10
Number of
patients
74 41 33 800 42 16 26 872
Potential follow-up, KM estimate (months)
Median (95% CI) 31.8 (26.5-36.1) 27.3 (25.5-NR) 34.2 (33.1-NR) 14.4 20.7 (20.7-30.3) 20.7 (19.7- NR) 26.9 (20.7-NR) 31.0
Observed follow-up (months)
Median (IQR) 12.6 (5.3-22.6) 16.5 (10.5-25.1) 7.8 (2.7-14.5) 15.6 (4.7-20.4) 19.4 (16.5-21.7) 9 (3.5-17.0)
Mean (SD) 14.6 (10.6) 14.1 (9.4)
Range 0.4-31.4 0.4-31.4
Total 1079.2 590.3
Patients alive
at censor date
18/74 (24%) 13/41 (32%) 5/33 (15%) 492/800 (62%) 17/42 (40%) 11/16 (69%) 6/26 (23%) 504/872 (58%)
Overall survival
(95% CI) (months)
12.6 (10.5-18.2) 18.2 (12.1-30.0) 7.8 (5.2-13.7) 18.4 (17.3-NR) 16 (9.8-NR) 19 (NR-NR) 9 (4.2-19.2) 35.3 (32.2-NR)
Abbreviations: CI, Confidence Interval; IQR, Inter Quartile Range; KM, Kaplan–Meier; NR, Not reached.
F IGURE 2 Kaplan-Meier survival curves, by indication (post and pre chemotherapy) and stratified by medicine and trial eligibility
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indicating that real-world outcomes are affected by an overall poorer
prognosis at treatment initiation. This, in turn, raises questions regard-
ing the appropriateness of inclusion criteria applied to RCTs—which
may be overly restrictive, resulting in trial populations which could
potentially diverge considerably from the patient populations subject
to treatment. Clinicians and patients are thus faced with the difficult
task of making treatment decisions based on extrapolating potential
patient benefits in clinical practice from clinical trial cohorts.
Our findings have allowed a better understanding of the effective-
ness of these medicines in real-life clinical practice. At an individual
patient level, the study results can be considered alongside clinical trial
findings to enable a more informed and enriched discussion of likely
treatment benefits, particularly in patients who do not fit trial eligibility
criteria—for example, in patients with poorer performance status. This
may be of particular benefit when medicines, including cancer treat-
ment, adversely affect a patient's quality of life. At a population level, it
is important to recognise that the effectiveness of new medicines
might not be as observed in trial patient cohorts used to inform HTA
models as a basis for payer/policy decision-making. This is not to say
that there is insufficient benefit (indeed our data show clear evidence
of the effectiveness in the real-world population), but it does highlight
uncertainties in the magnitude of both clinical benefits and, conse-
quently, cost-effectiveness. Hence, the availability of rich observational
data may inform a more iterative approach for assessing the value of
new medicines before and after adoption into clinical practice.
4.1 | Strengths and limitations
This study has several strengths: apart from its inclusiveness in terms
of study participants, its scope with regards to the medicines studied
is unprecedented (by analysing OS for both abiraterone and
enzalutamide, pre and post docetaxel chemotherapy). The compre-
hensiveness and richness of the data available facilitated the identifi-
cation of potentially trial-eligible patients, which in turn enabled us to
conduct the subgroup analysis; this provided a unique opportunity to
better compare trial results to those observed in clinical practice.
Nevertheless, there are also limitations to consider. First of all,
observational studies such as this are, by nature, non-randomised and
sized according to the underlying population. Consequently, there
were small numbers of patients in each group, and CIs were wide and
overlapped; hence, comparisons between our findings and RCT results
should be interpreted with caution. Furthermore, findings are subject
to confounding; however, attempts were made to adjust for con-
founding by using information available from electronic health
records. Second, this study did not set out to compare abiraterone
and enzalutamide treatments and cannot estimate the relative added
benefits of these treatments since there was no control arm. In addi-
tion, it was not possible to reproduce key efficacy outcomes as
reported from clinical trials; as unstructured, free text, or imaging data
were not available for analyses, determining progression-free survival,
for example, was not feasible. Third, required data were not always
available or were missing; for instance, 36% of patients had no
performance status recorded as this only became mandatory on the
chemotherapy electronic prescribing system in 2015, potentially
impacting the accuracy of results. Finally, the identification of patients
eligible for the pivotal clinical trials needs to be interpreted with cau-
tion; whilst certain eligibility criteria (eg, demographics and laboratory
test results) were easily and unambiguously identifiable within elec-
tronic patient records, other criteria were associated with a degree of
uncertainty. Identification of prior surgery, for example, was made
based on assumptions regarding included procedures.
5 | CONCLUSION
ERL of routinely collected healthcare data offers an opportunity to
report outcomes on cancer medicines at scale and describe patient
demographics whilst potentially identifying real-world patients ineligi-
ble for the pivotal studies. Such information may be valuable to
patients and clinicians to contextualise trial findings, and thus to make
more informed shared treatment decisions.
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